Clinical trials
Locally Advanced clinical trials
Below are recruiting locally advanced clinical trials, each written for real people, not researchers. We’re tracking 977 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07594925RecruitingPhase 2
Short-course radiation plus immunotherapy and chemotherapy for rectal cancer
This trial tests a combination of brief radiation therapy followed by immunotherapy and chemotherapy for locally advanced rectal cancer that hasn't spread. The goal is to see if this approach helps patients avoid or reduce surgery while controlling their cancer.
TianjinAges 18–75 - NCT07595835RecruitingPhase 1/Phase 2
Radioactive particles injected into pancreatic tumors
This trial tests a new treatment where doctors use imaging to guide radioactive particles directly into locally advanced pancreatic cancer tumors that haven't spread. The goal is to shrink or control the cancer with radiation delivered right to the tumor.
Amsterdam, North HollandAges 18 years+ - NCT07612176RecruitingPhase 1
Testing NEOK001 drug for advanced solid tumors
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
New York, New YorkAges 18 years+ - NCT07613723RecruitingPhase 1
Testing ZI-MA4-1 immunotherapy for advanced solid cancers
This early-stage trial tests a new type of immunotherapy called ZI-MA4-1 in patients with advanced cancers (ovarian, lung, synovial sarcoma, or head and neck) that have stopped responding to standard treatments. The therapy is designed to help your immune system recognize and fight cancer cells that have a specific protein called MAGE-A4.
LondonAges 18–75 - NCT07632235RecruitingPhase 1/Phase 2
Celecoxib with immunotherapy for bile duct cancer
This trial tests whether adding celecoxib (an anti-inflammatory pill) to pembrolizumab (an immunotherapy) and chemotherapy helps treat intrahepatic cholangiocarcinoma—a type of bile duct cancer that cannot be surgically removed. The goal is to see if this combination works better than the standard two-drug approach.
ShanghaiAges 18 years+ - NCT07638436RecruitingPhase 2
Immunotherapy with chemotherapy for advanced esophageal cancer
This trial tests whether combining a new immunotherapy drug (adebrelimab) with standard chemotherapy can help shrink borderline resectable esophageal squamous cell carcinoma before surgery. The goal is to make tumors easier to remove and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07638774Recruiting
Compression Gloves and Socks to Prevent Nerve Damage from UTD1 Cancer Drug
This study tests whether wearing special compression and cooling gloves and socks can help prevent nerve damage (numbness and tingling in hands and feet) that sometimes occurs in women receiving a breast cancer medication called UTD1. You would wear these gloves and socks during and after your chemotherapy treatment.
ShanghaiAges 18–75 - NCT07655024RecruitingPhase 2
TAIC plus FOLFOX for advanced stomach cancer
This trial tests a traditional Chinese medicine (TAIC) combined with chemotherapy (FOLFOX) for people with advanced stomach or gastroesophageal junction cancer that can't be removed with surgery. It aims to see if the combination can help shrink the tumor and improve survival.
BeijingAges 18 years+ - NCT07567716Enrolling by invitation
Study of How Advanced Esophageal Cancer Spreads After Surgery
This research examines tissue samples from patients who had surgery to remove advanced esophageal cancer in the neck or chest area. The study aims to understand how the cancer invaded surrounding tissues, which may help doctors better treat similar patients in the future.
ShanghaiAges Any age - NCT07550972Enrolling by invitationPhase 2
Combination drug treatment before surgery for advanced head and neck cancer
This study tests two drugs (pertuzumab and lenvatinib) given together before surgery for advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve outcomes for patients who haven't received prior cancer treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07542262Enrolling by invitationPhase 2
Low-dose immunotherapy for advanced colorectal and stomach cancer
This study tests a lower dose of immunotherapy in patients with colorectal or stomach cancer that has spread or cannot be removed by surgery. The cancer must have a specific genetic feature (MSI/dMMR). The goal is to see if this approach works well with fewer side effects.
MoscowAges 18 years+ - NCT07532928Enrolling by invitation
Personalized Post-Surgery Care Plan for Advanced Head and Neck Cancer
This study helps doctors create a personalized plan for follow-up treatment after surgery for advanced head and neck cancer. Researchers will use imaging scans and patient data to predict which patients need extra treatment and which ones can be monitored closely instead.
GuangzhouAges 18 years+ - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT06883136Enrolling by invitation
Sintilimab plus chemo for elderly advanced lung cancer
This trial tests a combination of the immunotherapy drug sintilimab plus standard chemotherapy (platinum-based doublet) as the first treatment for older adults (60–80) with advanced non-small cell lung cancer that does not have certain gene mutations. The goal is to see if this approach works better than chemotherapy alone.
Jinan, ShandongAges 60–80 - NCT06883084Enrolling by invitation
How lymph node changes affect rectal cancer outcomes
This trial looks at how much the lymph nodes respond to chemoradiation before surgery in people with locally advanced rectal cancer. It aims to understand if that response can predict long-term results and guide future treatment choices.
Ages 18–65 - NCT06714084Enrolling by invitation
Treating high-risk cervical cancer with chemoradiation and immunotherapy
This trial tests a new drug called Cardenimumab combined with standard chemotherapy and radiation for women with high-risk cervical cancer. The goal is to see if adding this drug can improve outcomes for patients whose tumors are large, have spread to lymph nodes, or are stage IV.
Wuhan, HubeiAges 18–75 - NCT06030947Recruiting
Micro graft for treating multiple gum recessions
This trial tests a new micro connective tissue graft to cover multiple areas where your gums have pulled away from your teeth (recession). It may help if you have healthy gums but several receding spots on your upper or lower jaw.
DubaiAges 18–60 - NCT07165067RecruitingPhase 1
Testing AP601 for advanced solid tumors that have not responded to treatment
This trial tests a new drug called AP601 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective, and it targets CD73 and CD137 pathways to help your immune system fight cancer.
Waratah, New South WalesAges 18 years+ - NCT06611137RecruitingPhase 2
SBRT plus chemoimmunotherapy to save the voice box
This trial tests a new approach to treat advanced larynx or hypopharynx cancer without removing the voice box. First, you get targeted radiation (SBRT), then a combination of chemotherapy and an immunotherapy drug called Toripalimab, which helps your immune system fight the cancer.
Guangzhou, GuangdongAges 18–70 - NCT06856187RecruitingPhase 2
Second-line chemo plus TAS-102 combo for advanced colorectal cancer
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
Shanghai, Shanghai MunicipalityAges Any age - NCT03046316Recruiting
Local treatment for advanced lung cancer that hasn’t worsened
This trial looks at whether using focused treatments (like surgery or radiation to lung cancer spots) can help people with advanced non-small cell lung cancer whose disease has not progressed after first-line treatment. It’s meant for people who have limited metastatic spots and can safely undergo the local treatment.
Guangzhou, GuagndongAges 18 years+ - NCT05801237RecruitingPhase 1/Phase 2
Study of two drugs for advanced solid tumors
This Phase 1/2 study tests two investigational medicines (PE0116 and PE0105) in people with advanced solid cancers that have spread or cannot be removed by surgery. It may help shrink tumors or slow disease when standard treatments have not worked or are not tolerated.
ShanghaiAges 18–75 - NCT07265921RecruitingPhase 1
Study of SIM0609 for advanced solid tumors
This trial tests an investigational new drug, SIM0609, for people with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see early signs that it might help slow or shrink tumors.
BeijingAges 18 years+ - NCT06190886RecruitingPhase 1
First-in-human study of PTX-912 for advanced solid tumors
This trial tests a new drug called PTX-912 for people with advanced or metastatic solid tumors that have not responded to standard treatments. It is a first-in-human study, meaning this is the first time PTX-912 is being given to people, to see how safe it is and how well it works.
Duarte, CaliforniaAges 18 years+
Hear when a new Locally Advanced trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced?
- Yes. Clin2 currently lists 977 recruiting locally advanced studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.